Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures
Authors:
- 18 August 2023
- journal article
- review article
- Published by Elsevier in The Lancet Haematology
- Vol. 10 (10) , e849-e859
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca plc
- AbbVie Inc
- Janssen Pharmaceuticals Inc
- ZonMw
This publication has 51 references indexed in Scilit:
- International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24Quality of Life Research, 2013
- Measuring the symptom burden associated with the treatment of chronic myeloid leukemiaBlood, 2013
- Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic reviewLeukemia Research, 2013
- Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) QuestionnaireValue in Health, 2012
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general populationBlood, 2011
- Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – A systematic review to evaluate the added value in supporting clinical decision makingEuropean Journal of Cancer, 2008
- Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based studyThe Lancet Oncology, 2006
- Participatory action researchJournal of Epidemiology and Community Health, 2006
- How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30Journal of Clinical Oncology, 2004
- Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS StudyJournal of Clinical Oncology, 2003